Eli Lilly Wins FDA Approval for New Weight Loss Pill

The pharmaceutical giant's once-daily oral drug Foundayo is set to compete with Novo Nordisk's Wegovy injection.

Apr. 1, 2026 at 10:23pm

Got story updates? Submit your updates here. ›

Eli Lilly announced that the U.S. Food and Drug Administration (FDA) has approved its new weight loss drug Foundayo, a once-daily oral pill that will compete with Novo Nordisk's injectable obesity medication Wegovy. Foundayo is set to begin shipping on April 6 through Eli Lilly's online sales platform, with self-pay options starting at $149 per month.

Why it matters

The approval of Foundayo is a significant milestone for Eli Lilly, as it marks the company's first approved weight loss medication in pill form. This could give Eli Lilly an advantage over Novo Nordisk's Wegovy, which requires weekly injections. The weight loss drug market is highly competitive, and Foundayo's convenience as a daily oral pill may help drive strong adoption and sales for Eli Lilly.

The details

Foundayo uses a different molecular compound than Eli Lilly's previous weight loss drug Zepbound, which is delivered by weekly injection. The company claims Foundayo is "obesity care designed for the real world" as a convenient, once-daily oral pill. While Wegovy has reported higher weight loss results in clinical trials, Eli Lilly has significantly more resources to market and distribute Foundayo compared to Novo Nordisk.

  • Foundayo will begin shipping on April 6, 2026.
  • The FDA approved Foundayo before market open on April 1, 2026.

The players

Eli Lilly

A major American pharmaceutical company that has now received FDA approval for its new weight loss drug Foundayo, an oral pill that will compete with Novo Nordisk's injectable Wegovy.

David Ricks

The CEO of Eli Lilly, who was quoted saying Foundayo is "obesity care designed for the real world" as a convenient, once-daily oral pill.

Novo Nordisk

A Danish pharmaceutical company that makes the injectable weight loss drug Wegovy, which will now compete with Eli Lilly's new oral pill Foundayo.

Got photos? Submit your photos here. ›

What they’re saying

“As a convenient, once-daily oral pill that delivers meaningful weight loss, this is obesity care designed for the real world.”

— David Ricks, CEO, Eli Lilly

What’s next

Foundayo will begin shipping through Eli Lilly's LillyDirect online sales platform starting on April 6, 2026.

The takeaway

Eli Lilly's approval of its new weight loss pill Foundayo represents a significant competitive advantage over rival Novo Nordisk's injectable Wegovy, as the convenience of a daily oral medication may drive stronger adoption and sales for Eli Lilly in the lucrative obesity drug market.